Novartis Not Tempted To Join COVID-19 Vaccines Race
No Longer Has Capabilities After GSK Asset Swap
While the traditional players such as Pfizer and GSK, as well as newcomer AstraZeneca, are hot in pursuit of a COVID-19 vaccine, the Swiss major is sticking to drugs, the area where "we do have deep expertise," CEO Vas Narasimhan told journalists.
